- Completed
NCT02336815 : Phase 2 - Selinexor Treatment of Refractory Myeloma (STORM)
Updated: Jun 21, 2022
STORM
Selinexor Treatment of Refractory Myeloma (STORM)
This is a Phase 2b, single-arm, open-label, multicenter study of selinexor 80 mg plus dexamethasone 20 mg (Sd) dosed twice weekly in four-week cycles, in patients with penta-refractory MM (Parts 1 and 2) or quad refractory MM (Part 1 only).
Sponsor:
Karyopharm Therapeutics Inc
Multiple Locations
International Study
ClinicalTrials.gov Identifier: NCT02336815
Official Title: A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
First Posted : January 13, 2015
Click here for details on ClinicalTrials.gov
Drug: Selinexor
Drug: Dexamethasone
PMID: 31433920
N Engl J Med; Aug 2019
PMID: 29381435
J Clin Oncol; March 2018
Locations
United States, Alabama
United States, Arizona
United States, California
United States, Connecticut
United States, Florida
United States, Georgia
United States, Hawaii
United States, Illinois
United States, Indiana
United States, Iowa
United States, Kentucky
United States, Maryland
United States, Massachusetts
United States, Michigan
United States, Minnesota
United States, Missouri
United States, New Jersey
United States, New York
United States, North Carolina
United States, Ohio
United States, Oregon
United States, Pennsylvania
United States, Tennessee
United States, Texas
United States, Washington
Europe
Austria
Belgium
France
Germany
Greece